OBJECTIVE -Animal and in vitro studies indicate that a decrease in ␤-cell insulin secretion, and thus a decrease in tonic ␣-cell inhibition by intraislet insulin, may be an important factor for the increase in glucagon secretion during hypoglycemia. However, in humans this role of decreased intraislet insulin is still unclear.
D
efense against hypoglycemia normally involves inhibition of endogenous insulin secretion and increased release of several counterregulatory hormones, of which glucagon is considered to be most important (1,2). Epinephrine responses, although normally not critical for the defense against hypoglycemia, become critical when glucagon secretion is deficient (1,2). In type 1 diabetes, glucagon responses to hypoglycemia are universally lost early in the course of the disease (3). This abnormality therefore plays a key role in the development of defective glucose counterregulation when patients subsequently develop reduced epinephrine responses (3). The clinical importance of this condition is illustrated by the fact that the combined defect in glucagon and epinephrine responses is associated with at least a 25-fold increased risk for severe hypoglycemia (4,5), the major limiting factor for obtaining near-normal glycemic control (6).
Various hypotheses have emerged to explain the loss of glucagon response to hypoglycemia in type 1 diabetes including disruption of islet architecture (7), autonomic neuropathy (8 -10), and loss of glucoreception (11, 12) . Although these factors may contribute, several observations suggest that none of these is a complete explanation. First, glucagon responses to stimuli other than hypoglycemia are largely, if not entirely, intact in type 1 diabetes (11,13), suggesting a signaling rather than a structural abnormality of ␣-cells. Secondly, counterregulatory glucagon responses were found to be unaltered by autonomic blockade using adrenergic and cholinergic antagonists in humans (14, 15) and glucagon secretion by the denervated allografted pancreas increases during hypoglycemia (16) , suggesting that autonomic neuropathy may not be the key factor. Finally, isolated viable ␣-cells from cadaveric pancreas donors have been found not to release glucagon in response to a low glucose medium (17) , indicating that in humans the increased glucagon release in response to hypoglycemia may not depend solely on ␣-cell glucoreception.
Because insulin normally inhibits glucagon release, Samols et al. (18) proposed more than 30 years ago that a decrease in ␤-cell insulin secretion, and thus a decrease in tonic intraislet ␣-cell inhibition by insulin, may be the signal for increased glucagon secretion during hypoglycemia. According to this concept, absence of a decrease in intraislet insulin due to the lack of ␤-cells would be a plausible explanation for the blunted glucagon responses to hypoglycemia in type 1 diabetes. This so-called intraislet insulin hypothesis is supported by the observation that the loss of glucagon responses is linked to the loss of ␤-cell function in patients with type 1 diabetes in most (19, 20) but not all (21) studies and by the finding that counterregulatory glucagon responses deteriorate with progression of ␤-cell failure in patients with type 2 diabetes (22) .
Further evidence for the intraislet insulin hypothesis has recently been provided by animal and in vitro studies (23, 24) , which indicate that both normal isolated human and rat islets and islets from streptozotocin-administered rats (which characteristically do not release glucagon when exposed to a very low glucose concentration) can respond to glucose deprivation by releasing glucagon if they are first provided with increased endogenous or exogenous insulin. These studies also demonstrated that in streptozotocin-induced diabetic rats with near complete ␤-cell failure, glucagon responses to hypoglycemia, which had been absent, were restored when the decrement in intraislet insulin was reestablished by an infusion of insulin into the superior pancreaticoduodenal artery that was switched off when blood glucose level fell to Ͻ60 mg/dl (24) . However, whether these animal and in vitro studies are relevant to human physiology is unclear.
Definite evidence for the intraislet insulin hypothesis in humans has yet to be provided. Banarer et al. (25) reported that in normal subjects counterregulatory glucagon responses were blunted when the fall in intraislet insulin during hypoglycemia was prevented by infusion of the ins u l i n s e c r e t a g o g u e t o l b u t a m i d e . However, in these studies intraislet insulin increased above baseline during the tolbutamide infusion and because insulin suppresses glucagon release (26) , the blunted glucagon responses might have been merely the result of tolbutamideinduced intraislet hyperinsulinemia.
This study was therefore undertaken to retest the intraislet insulin hypothesis in humans using an experimental design that would obviate previous interpretative difficulties. To this end, we examined counterregulatory plasma glucagon responses of healthy subjects on two separate occasions. On one occasion, the subjects' insulin secretion was suppressed before induction of hypoglycemia by an infusion of somatostatin, which was stopped once hypoglycemia had developed so that the decrement in intraislet insulin during hypoglycemia would be reduced. On the other occasion, subjects received an infusion of normal saline before inducing hypoglycemia so that the decrement in intraislet insulin during hypoglycemia would not be reduced.
RESEARCH DESIGN AND
METHODS -Informed written consent was obtained from 14 healthy volunteers after the protocol had been approved by the University of Rochester Institutional Review Board. Subjects (4 men and 10 women) were 36.4 Ϯ 3.8 years of age and had BMI of 26.3 Ϯ 1.7 kg/m 2 . All subjects had normal fasting glucose tolerance according to American Diabetes Association criteria (27) and no family history of diabetes.
All subjects were studied on two separate occasions at least 1 week apart. For each study, subjects were admitted to the University of Rochester General Clinical Research Center between 5:00 and 6:00 P.M. the evening before experiments, received a standard dinner (10 kcal/kg: 50% carbohydrate, 35% fat, and 15% protein) between 6:30 and 7:00 P.M. and fasted thereafter until the experiments were completed.
At ϳ7:00 A.M. the following morning, a retrograde venous catheter was inserted into a dorsal hand vein and kept in a thermoregulated Plexiglas box at 65°C for sampling arterialized venous blood (28) . Approximately 1 h later, two blood samples were collected at 30-min intervals (Ϫ90 and Ϫ60 min) for measurement of baseline concentrations of plasma glucose, insulin, C-peptide, glucagon, epinephrine, norepinephrine, growth hormone, and cortisol. At Ϫ60 min, a 2-h intravenous infusion of somatostatin (500 g/h) was begun on one occasion to artificially reduce the decrement of intraislet insulin during the subsequent hypoglyce- mic clamp; on the other occasion, an infusion of normal saline was given instead. Infusions were given in a single-blinded randomized fashion. During the 1st h of the infusions, plasma glucose concentrations were maintained at baseline levels. At 0 min, a continuous infusion of insulin (1 mU ⅐ kg Ϫ1 ⅐ min Ϫ1 ) was begun, and plasma glucose concentrations were allowed to decrease to 45-50 mg/dl (2.5-2.8 mmol/l) during the following 60 min. At the end of this period (60 min), the infusion of somatostatin or normal saline was stopped, and plasma glucose concentrations were maintained at 45-50 mg/dl until 120 min using the glucose clamp technique (29) . Blood samples were collected as described above at Ϫ30, 0, 30, 60, 75, 90, 105, and 120 min.
Analytical procedures
Blood samples were collected for plasma insulin, C-peptide, glucagon, cortisol, and growth hormone in EDTA tubes containing a protease inhibitor and for plasma catecholamines in EGTA tubes.
Plasma glucose was immediately determined in duplicate with a glucose analyzer (Yellow Springs Instrument). For other determinations, samples were placed immediately in a 4°C ice bath, and plasma was subsequently separated by centrifugation at 4°C. Plasma samples of both experiments of a given subject were analyzed in the same assay. Plasma insulin, C-peptide, glucagon, growth hormone, and cortisol concentrations were determined by standard radioimmunoassays. Plasma glucagon was determined by a double antibody radioimmunoassay (Linco Research, St. Charles, MO) with an intra-assay coefficient of variation of 5.9% and a sensitivity of 20 -400 ng/l. Plasma epinephrine and norepinephrine concentrations were measured by a radioenzymatic method as previously described (30) .
Calculations
Rates of insulin secretion were calculated by deconvolution analysis of plasma Cpeptide using an open two-compartmental model (31, 32) and population-based transition coefficients (33) as described by Hovorka and Jones (34) . The software (ISEC Version 2) was kindly provided by Dr. R. Hovorka, Center for Measurement and Information in Medicine, City University, London, U.K.
Statistical analyses
Unless stated otherwise, data are expressed as means Ϯ SEM. Paired twotailed Student's t tests were used to compare corresponding data for both sets of experiments. Because secretion of glucagon and growth hormone is suppressed by somatostatin, means of plasma glucagon and growth hormone concentrations at 105 and 120 min and the increments of these means above baseline (mean of Ϫ90 and Ϫ60 min) were used for comparisons. Thus, at least 45 min were allowed for achievement of maximum plasma glucagon and growth hormone levels in response to hypoglycemia after the somatostatin infusion had been discontinued (60 min). This 45-min interval was chosen because, at a constant glucagon secretion, steady-state plasma glucagon levels would be achieved within 30 min (i.e., at least 5 ϫ the 3-6 min t 1/2 of plasma glucagon) (35) .
RESULTS
Plasma glucose, insulin, C-peptide, and glucagon At baseline plasma glucose, insulin, Cpeptide, and glucagon concentrations as well as rates of insulin secretion were comparable in both sets of experiments (Figs. 1-3 ). Plasma glucose, insulin, Cpeptide, and glucagon concentrations and rates of insulin secretion remained unchanged from baseline during infusion of saline until the insulin infusion was begun. Over the comparable period during which somatostatin was infused, plasma glucose decreased to levels that were slightly lower than those in the saline experiment (4.4 Ϯ 0.2 vs. 5.4 Ϯ 0.1 mmol/l immediately before the start of the insulin infusion, P Ͻ 0.01); plasma concentrations of insulin, C-peptide, and glucagon and rates of insulin secretion decreased to levels that were significantly lower than those in the saline experiment ( 2-h insulin infusion, plasma insulin levels were comparable in the saline and somatostatin experiments (548 Ϯ 41 and 588 Ϯ 52 pmol/l, respectively, P ϭ 0.11).
Over the initial 60 min of the insulin infusion while somatostatin or saline was being infused, plasma glucose decreased to slightly lower levels in the somatostatin experiments (2.2 Ϯ 0.1 vs. 2.6 Ϯ 0.1 mmol/l, P Ͻ 0.001). However, during the final hour of the insulin infusion when somatostatin or saline was no longer being infused, plasma glucose levels were virtually identical in both sets of experiments (2.6 Ϯ 0.1 vs. 2.6 Ϯ 0.1 mmol/l, P ϭ 0.68).
Plasma C-peptide decreased to significantly lower levels in the somatostatin experiments during the initial 60 min of the insulin infusion (82 Ϯ 8 vs. 159 Ϯ 13 pmol/l, P Ͻ 0.001) and the final hour of the insulin infusion when somatostatin or saline was no longer being infused (52 Ϯ 6 vs. 82 Ϯ 12 pmol/l, P Ͻ 0.004). However, because plasma C-peptide had been suppressed before the insulin infusion in the somatostatin experiments, decrements of plasma C-peptide during the entire insulin infusion period (99 Ϯ 28 vs. 354 Ϯ 32 pmol/l, P Ͻ 0.001) and the last hour of the insulin infusion (29 Ϯ 6 vs. 77 Ϯ 14 pmol/l, P Ͻ 0.009) were markedly reduced compared with the saline experiments.
In the saline experiments, rates of insulin secretion, calculated using deconvolution analysis of plasma C-peptide, decreased to 1.01 Ϯ 0.12 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 (P Ͻ 0.001) during the first hour of the insulin infusion but did not decrease further during the final hour of the insulin infusion (Ϫ0.03 Ϯ 0.04 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 , P ϭ 0.45). In the somatostatin experiments, because insulin secretion had been suppressed ϳ80% before the insulin infusion, insulin secretion did not decrease during the 1st h of the insulin infusion (Ϫ0.09 Ϯ 0.11 pmol ⅐ kg Ϫ1 ⅐ min
Ϫ1
, P ϭ 0.41), the final hour of the insulin infusion (Ϫ0.03 Ϯ 0.02 pmol ⅐ kg Ϫ1 ⅐ min
, P ϭ 0.21), or the entire insulin infusion period (Ϫ0.12 Ϯ 0.10 pmol ⅐ kg Ϫ1 ⅐ min Ϫ1 , P ϭ 0.26) indicating the complete lack of a decrement in intraislet insulin during hypoglycemia.
Compared with values before insulin infusion, plasma glucagon increased approximately twofold in saline experiments during the initial 60 min of the insulin infusion (65 Ϯ 3 vs. 133 Ϯ 8 ng/l, P Ͻ 0.001) but remained unchanged in the somatostatin experiments (50 Ϯ 3 vs. 50 Ϯ 4 ng/l; NS). After discontinuation of the somatostatin infusion, plasma glucagon increased within 15 min and plateaued during the last three sampling times, indicating that sufficient time was allowed for maximum plasma glucagon levels to occur in response to hypoglycemia. During the last 15 min of the insulin infusion, both the absolute values (109 Ϯ 7 vs. 136 Ϯ 9 ng/l, P Ͻ 0.006) and the increments above baseline of plasma glucagon (41 Ϯ 8 vs. 67 Ϯ 11 ng/l, P Ͻ 0.008) were significantly reduced in the somatostatin experiments.
Plasma epinephrine, cortisol, and growth hormone Baseline plasma epinephrine, cortisol, and growth hormone levels were comparable in saline and somatostatin experiments (Fig. 4) . During the infusion of insulin, plasma epinephrine increased earlier in the somatostatin experiments, probably because of lower plasma glucose levels. However, during the last hour of the insulin infusion, increments above baseline of epinephrine in saline and somatostatin experiments were not significantly different (4,110 Ϯ 567 vs. 3,840 Ϯ 508 pmol/l, P ϭ 0.40). Increments of plasma norepinephrine during the same interval were also not significantly different in saline and somatostatin experiments (902 Ϯ 197 vs. 920 Ϯ 204 pmol/l, P ϭ 0.87). Similarly, increments in plasma cortisol during this interval were comparable in saline and somatostatin experiments (268 Ϯ 28 vs. 299 Ϯ 33 nmol/l, P ϭ 0.35).
Before the infusion of insulin, plasma growth hormone did not change during the infusion of saline but decreased about 40% during the infusion of somatostatin (P Ͻ 0.01). However, increments of plasma growth hormone above baseline values during the last 15 min of the insulin infusion were significantly greater in the somatostatin than in the saline experiments (23.8 Ϯ 4.8 vs. 14.2 Ϯ 3.8 g/l, P Ͻ 0.007).
CONCLUSIONS -This study was designed to examine the intraislet insulin hypothesis in humans using an approach that would simulate the conditions in type 1 diabetes patients, who lack the fall in intraislet insulin during hypoglycemia because of the complete loss of ␤-cell function. We infused somatostatin to suppress insulin release before hypoglycemia so that the decrement in insulin secretion during hypoglycemia would be minimized. As indicated by deconvolution analysis of plasma C-peptide, insulin secretion was suppressed ϳ80% by somatostatin before the infusion of insulin so that insulin secretion did not further decrease during hypoglycemia, including the period when somatostatin was no longer being infused and glucagon secretion was no longer being inhibited. This absent decrement in insulin secretionand thus intraislet insulin-was associated with ϳ30% lower absolute and incremental plasma glucagon concentrations during hypoglycemia.
Because glucagon secretion was suppressed by the somatostatin infusion, it may be argued that glucagon responses to hypoglycemia should have been assessed using increments in plasma glucagon after the somatostatin infusion rather than using absolute plasma concentrations or increments above baseline. It is of note, however, that because of the short t 1/2 of plasma glucagon, plasma glucagon concentrations reach a steady state within ϳ30 min of a constant glucagon delivery into the systemic circulation (36, 37) . Consequently, despite the fact that plasma glucagon had been suppressed by somatostatin, plasma glucagon concentrations would be expected to be similar at the end of the hypoglycemic clamp in both experiments if glucagon secretion were comparable. We found, however, that after the somatostatin infusion had been stopped, plasma glucagon increased rapidly and plateaued after 30 min at levels that were ϳ30% lower than in the saline experiments. Moreover, plasma growth hormone, which had also been suppressed by somatostatin, was actually increased to a greater extent at the end of the hypoglycemic period than in the saline experiments. These observations therefore indicate that the reduced glucagon responses in the somatostatin experiments were neither the consequence of our approach to analyze the data nor due to residual effects of somatostatin inhibiting the release of glucagon into the circulation.
In the present studies, plasma glucose concentrations were slightly lower during the somatostatin infusion than during the saline infusion until these infusions were stopped. It may thus also be argued that the reduced glucagon responses in the somatostatin experiments were the result of lower antecedent glycemia rather than the reduced decrement in intraislet insulin. However, the following considerations cast doubt on this notion. First, in the somatostatin experiments plasma glucose concentrations were at all times well above the glycemic threshold for stimulation of glucagon secretion (ϳ3.8 mmol/l) (38) before the insulin infusion and were only 0.4 mmol/l lower than in the saline experiments at the end of the 1st h of the insulin infusion. During the final hour of the insulin infusion, during which somatostatin or normal saline was no longer being infused, plasma glucose concentrations were virtually identical on both occasions. Second, if the lower antecedent glycemia was responsible for the reduced glucagon responses in the somatostatin experiments, one would expect gradually decreasing glucagon responses during prolonged hypoglycemia. This has, however, not been observed in several previous studies (39 -41) . Third, the slightly lower plasma glucose concentrations during the 1st h of the insulin infusion in the somatostatin experiments would be expected, if anything, to have caused increased accumulation of glucagon in the ␣-cells. This would have been available for release after somatostatin was stopped and resulted in greater but not lower glucagon responses. The final consideration, and perhaps the most compelling, is that in a subanalysis using the data of only half of our subj e c t s i n w h o m p l a s m a g l u c o s e concentrations of both experiments were well matched, similar results were obtained for glucagon responses. In these subjects, except for slightly lower levels from Ϫ30 to 0 min in the somatostatin experiments (5.0 Ϯ 0.2 vs. 5.4 Ϯ 0.1 mmol/l, P Ͻ 0.02), plasma glucose concentrations were virtually identical on both occasions (2.5 Ϯ 0.1 vs. 2.6 Ϯ 0.1 mmol/l at 60 min, P ϭ 0.48; 2.6 Ϯ 0.1 vs. 2.6 Ϯ 0.1 mmol/l during the last hour of the insulin infusion, P ϭ 0.84). As in all 14 subjects, plasma glucagon concentrations (116 Ϯ 6 vs. 137 Ϯ 6 ng/l, P Ͻ 0.01) and increments of plasma glucagon above baseline (48 Ϯ 6 vs. 69 Ϯ 6 ng/l, P Ͻ 0.02) during the last 15 min of the hypo- glycemic clamp were significantly reduced when the decrement in intraislet insulin was prevented by the antecedent somatostatin infusion. These observations not only indicate that differences in the antecedent glycemia had very little if any effect on the counterregulatory glucagon responses but also that our findings are quite robust.
The finding that glucagon responses were only 30% lower in the somatostatin than in the saline experiments suggests that a decrement in intraislet insulin may not be essential for increased glucagon secretion in response to hypoglycemia and that factors other than the lack of the decrement of intraislet insulin may be involved in the blunted glucagon responses in type 1 diabetes patients. It is of note, however, that our results might underestimate the importance of the decrement in intraislet insulin for two reasons. First, the observed glucagon response during hypoglycemia in the somatostatin experiments might have reflected a rebound of glucagon secretion following discontinuation of the somatostatin infusion owing to accumulated ␣-cell hormone rather than an actual response to hypoglycemia. This concept would be consistent with the finding of Gerich et al. (42) that, despite mild hyperglycemia, plasma glucagon increased rapidly to levels that were approximately threefold greater than baseline after prolonged somatostatin infusion in type 1 diabetes subjects. Moreover, it is supported by the finding of the present study that plasma growth hormone responses were ϳ70% greater after the infusion of somatostatin than normal saline. Second, we cannot rule out the possibility that in the somatostatin experiments, the decrement in intraislet insulin before hypoglycemia provided a signal for glucagon secretion once hypoglycemia was established and somatostatin was no longer being infused. In other words, a glucagon response, albeit diminished, might have occurred because a ␤-cell signal (decreased insulin secretion) was provided in advance of hypoglycemia when it would normally happen during hypoglycemia.
In the present studies, glucagon responses to hypoglycemia were assessed during the last 15 min of a fixed 2-h insulin infusion, which resulted in physiologic and similar hyperinsulinemia in both sets of experiments. Moreover, most previous studies have found that in humans counterregulatory glucagon responses are not affected by the degree of peripheral hyperinsulinemia within the physiologic range (43) (44) (45) (46) (47) , indicating that our findings were not the result of differences in peripheral plasma insulin levels. Mellman et al. (46) found ϳ25% reduced glucagon responses after prolonged (3.5 h) compared with short (30 min) peripheral hyperinsulinemia, suggesting that the duration of antecedent hyperinsulinemia may have an influence. It is thus possible that the magnitude of glucagon responses might have been different in the present study if we had used a different duration of the insulin infusion. Nevertheless, we know of no evidence suggesting that the relative importance of the decrement in intraislet insulin for counterregulatory glucagon responses may vary with different durations of antecedent hyperinsulinemia.
In summary, the present study indicates that a decrement in intraislet insulin is an important factor for increased glucagon secretion during hypoglycemia in humans consistent with the intraislet insulin hypothesis. However, it remains unclear whether the decrement in intraislet insulin is an essential signal for the increased glucagon secretion and to what extent the lack of a decrement in intraislet insulin accounts for the blunted glucagon responses in patients with type 1 diabetes.
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Note added in proof
After the submission of this article, Raju and Cryer (48) reported findings consistent with those of the present study using a similar study design. In that study, oral diazoxide was given prior to inducing hypoglycemia, so that the decrement in plasma C-peptide during hypoglycemia was ϳ50% reduced compared with control experiments. This was associated with an ϳ50% reduction in counterregulatory glucagon responses, further supporting the intraislet hypothesis in humans. 
